We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/12/2020 18:45 | Is it not just dilution from placing? | harrywilliam | |
16/12/2020 18:37 | Perhaps it has been responsible for decline since October and is now finished? | small crow | |
16/12/2020 18:23 | Agree smallcrow - a bit worrying that the Wales Life Sciences Investment Fund have halved. | rotors | |
16/12/2020 18:13 | Some big-hitters bailing out. Worrying or just tidying up before new year?? | small crow | |
15/12/2020 10:31 | Do you have a price target here Stig? | hodhasharon | |
11/12/2020 19:51 | I bet he won't tell you before he sells them? | deutsch4 | |
11/12/2020 18:17 | Didn't realise former analyst Mark McNulty was a holder here Should help this get noticed by the herd soon "After being scaled back, I've received 240k shares in the #RENE placing. An incredibly exciting business: I have very high hopes for this new position. Will begin commentary in 3 weeks, once the GM has passed and the fundraise has completed." | the stigologist | |
11/12/2020 14:52 | NEWS 11 DECEMBER 2020 Exosome-based candidates move into the clinic Exosomes — small extracellular vesicles that are shed by cells — have long offered promise as drug delivery systems for small molecules, DNA, RNA and other biologic payloads. The first of these are now in the clinic. | the stigologist | |
11/12/2020 07:38 | Over subscribed...should help. | rayrac | |
09/12/2020 08:39 | Edison valuation now £190m i.e. over 300p+ per share | the stigologist | |
05/12/2020 09:02 | Agreed parc1. My understanding is that, as well as working on their internal programs, they have three collaborations with third parties underway with another two in negotiation. If even one of the initial programs proves successful, the commercial implications will be significant and the valuation would change pretty significantly. | whatno | |
05/12/2020 07:02 | Thanks Onceaday. Exosomes are known to cross the blood brain barrier. It is probable that they can carry a drug. So its about the combination not being seen as a contaminant and also attachment not affecting efficacy / potency. A lot of licencing deals are possible here making for a greater knowledge base. When just one company finds a solution it could potentially open the door (or barrier) for many more. | parc1 | |
04/12/2020 23:32 | Hi parc1 I'm not an expert by any means. All I have learned is that the BB barrier is extremely efficient in protecting the brain from contaminants carried in the bloodstream. This meams that therapeutics given often fail simply because they never reach their intended target (the brain). As you rightly point out, MH has explained the potential for exosomes to act as carriers for various compounds across the BB barrier. I can equate this to technology that Emisphere developed to improve poorly absorbed compounds in the digestive tract. The technology was used by Novo Nordisk for a diabetes drug and they subsequently bought out Emisphere - presumably to avoid paying the royalties that were due. | onceaday | |
04/12/2020 22:50 | Exosome Platform - Michael Hunt "..Well I think for us, for Reneuron, it is another string to our bow. Certainly we see potential here to sign a number of deals that help third parties deliver their drugs using our exosome technology from which and these deals of course will we hope would give Reneuron through milestones as our exosomes are married with those particular third party drugs if successful. So as I say it is a new platform for us but derived from something frankly that we have been working on for over a decade - notably our CTX line and it is worth noting that the one advantage that we believe we have in this field, in the exosome field is our CTX line is a very efficient producer of exosomes. So, I suppose in a sense, what we are doing is leveraging stuff we already have to give ourselves another platform which itself offers a lot of commercial potential in our view over the years ahead.." "..We see it as all upside if we can show real progress and success using this platform in that setting then there has to be a good deal of value in it for Reneuron and that obviously we hope would be very beneficial for our own stakeholders.." | parc1 | |
04/12/2020 22:11 | Onceaday can you please fill me in with some info on exosomes. To be honest, I have read up on it and note a recent paper. Exozomes are 30-150nm size. Initially they were thought to be cell debris (as you all know). They actually need ultracentrifugation to separate them from cell debris. As for passing the blood brain barrier.. "..Although one study showed that nanoparticles of about 200-nm size range are able to cross BBB (Olivier et al., 1999), another study contraindicated this result using 300-nm particle size (Kreuter et al., 2003).." I am not a biochemist and would value your knowledge on the obstacles presented in passing the BBB. I would imagine if Kreuter achieved 300nm then 30-150nm is no stretch. If you can shed some light on the blood brain barrier issue it would be appreciated. | parc1 | |
04/12/2020 08:10 | Excellent Onceaday. Thanks So Reneuron is trading at 15% of Edison's 26 August 2020 valuation - based on RP and not factoring in exosomes. | parc1 | |
03/12/2020 22:51 | Actually, your valuation is out of date... If you look on the Edison Reneuron page you will find "We have revised our valuation to £170m from £107m." That valuation is based on the RP program. They state that exosomes can't be valued. However, if RENE are succeasfull in providing a carrier for therapeutics to cross the blood brain barrier then this could result in multiple high value licensing deals. That's probably.why the directors shelled out £1.1m in the placing. | onceaday | |
03/12/2020 21:32 | Prior to Reneuron's recent successful Fundraise, In June 2020 Edison valued the company at £107m. Further positive and sustained top-line efficacy data on RP trial and with funding now in place, total cash runway is 10 quarters, Reneuron market cap is £25.8m Reneuron is trading at 24% of Edison's June valuation. | parc1 | |
03/12/2020 08:02 | You're quite right, Rayrac. | dogwalker | |
03/12/2020 07:15 | There’s no financial return from investing in a charity..but I can see your drift. High risk, high return, is the hope here? | rayrac | |
02/12/2020 20:51 | There is lots of research underway in vision preservation/enhance | onceaday | |
02/12/2020 18:48 | Curious that RENE don't even get a mention in this, when they seem to be a long way ahead... | supernumerary |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions